CIK 0001527728 · Non-accelerated filer<br>Smaller reporting company
Lunai Bioworks Inc.
Sign in to watch- Ticker
- LNAI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 452259340
- Phone
- 45 39179840
- Business address
- CENTURY CITY MEDICAL PLAZA, 2080 CENTURY CITY EAST, SUITE 906 LOS ANGELES, CA, 90067
- Former names
- RENOVARO INC., RENOVARO BIOSCIENCES INC., Enochian Biosciences Inc, DanDrit Biotech USA, Inc., Putnam Hills Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-13 | Dybul Mark Chief Executive Officer | Grant or award · Option to Purchase Common Stock | +5,226 | 5,226 | ||
| 2024-02-13 | Dybul Mark Chief Executive Officer | Returned to the company · Option to Purchase Common Stock | −300,000 | 0 | ||
| 2024-02-13 | Dybul Mark Chief Executive Officer | Grant or award · Option to Purchase Common Stock | +300,000 | 300,000 | ||
| 2024-02-13 | Dybul Mark Chief Executive Officer | Returned to the company · Option to Purchase Common Stock | −450,000 | 0 | ||
| 2024-02-13 | Dybul Mark Chief Executive Officer | Grant or award · Option to Purchase Common Stock | +450,000 | 450,000 | ||
| 2024-02-13 | Dybul Mark Chief Executive Officer | Returned to the company · Option to Purchase Common Stock | −2,000,000 | 0 | ||
| 2024-02-13 | Dybul Mark Chief Executive Officer | Grant or award · Option to Purchase Common Stock | +2,000,000 | 2,000,000 | ||
| 2024-02-13 | Dybul Mark Chief Executive Officer | Returned to the company · Option to Purchase Common Stock | −350,000 | 0 | ||
| 2024-02-13 | Dybul Mark Chief Executive Officer | Grant or award · Option to Purchase Common Stock | +350,000 | 350,000 | ||
| 2024-02-13 | Sindlev Rene Director | Conversion | +701,260 | 13,133,598 | ||
| 2024-02-13 | Sindlev Rene Director | Conversion · Series A Convertible Preferred Stock | −70,126 | 0 | ||
| 2023-12-27 | Brosgart Carol L Director | Grant or award · Option to purchase shares of common stock | +23,810 | 23,810 | ||
| 2023-12-27 | Alton Gregg H Director | Grant or award · Option to purchase shares of common stock | +23,810 | 23,810 | ||
| 2023-10-23 | Miller Avram Director | Grant or award | +1,000,000 | 1,000,000 | ||
| 2023-10-23 | Miller Avram Director | Grant or award · Option to purchase shares of common stock | +27,147 | 27,147 | ||
| 2023-10-09 | Gronfeldt-Sorensen Henrik Director | Grant or award · Option to purchase shares of common stock | +17,242 | 17,242 | ||
| 2023-10-04 | Hendriks Ruud Director | Grant or award · Option to purchase shares of common stock | +16,129 | 16,129 | ||
| 2023-10-04 | Boeren Leni Director | Grant or award · Option to purchase shares of common stock | +16,129 | 16,129 | ||
| 2023-10-03 | Abildgaard Ole 10% owner | Grant or award | +500,000 | 7,398,482 | ||
| 2023-08-22 | Abildgaard Ole 10% owner | Grant or award | +500,000 | 6,898,482 |
Page 4 of 10 · 198 trades